Mismatch repair, minichromosome maintenance complex component 2, cyclin A, and transforming growth factor β receptor type Ⅱ as prognostic factors for colorectal cancer: results of a 10-year prospective study using tissue microarray analysis
- Author:
- No author available
- Journal Title:
- CHINESE MEDICAL JOURNAL
- Issue:
- 4
- DOI:
- 10.3760/cma.j.issn.0366-6999.2011.04.001
- Key Word:
- colorectal cancer;tissue microarray;immunohistochemistry;prognostic markers
Abstract： Background The expression of genes encoding a number of pathogenetic pathways involved in colorectal cancer could potentially act as prognostic markers. Large prospective studies are required to establish their relevance to disease prognosis.Methods We investigated the relevance of 19 markers in 790 patients enrolled in a large randomised trial of 5-fluorouracil using immunohistochemistry and chromogenic in situ hybridisation. The relationship between overall 10-year survival and marker status was assessed.Results Minichromosome maintenance complex component 2 (MCM2) and cyclin A were significantly associated with overall survival. Elevated MCM2 expression was associated with a better prognosis (HR=0.63, 95%CI: 0.46-0.86).Cyclin A expression above the median predicted an improved patient prognosis (HR=0.71, 95%CI: 0.53-0.95). For mismatch repair deficiency and transforming growth factor β receptor type Ⅱ (TGFBRII) overexpression there was a borderline association with a poorer prognosis (HR=0.69, 95%C/: 0.46-1.04 and HR=2.11, 95%CI: 1.02-4.40,respectively). No apparent associations were found for other markers.Conclusion This study identified cell proliferation and cyclin A expression as prognostic indicators of patient outcome in colorectal cancer.
- [1]San-Hua Qing,Kai-Yun Rao,Hui-Yong Jiang,etc.Racial differences in the anatomical distribution of colorectal cancer: a study of differences between American and Chinese patients[J].2003,(4).
- [2]Terracciano L,Al-Kuraya K,Al-Dayel F,etc.HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.[J].2007,60(7).
- [3]Abeer A, Bahnassy,Abdel-Rahman N, Zekri,Soumaya, El-Houssini,etc.Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients.[J].2004,4.
- [4]C R, Boland,S N, Thibodeau,S R, Hamilton,etc.A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.[J].1998,58.
- [5]Matsuno Y,Tamura T,Kunitoh H,etc.Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.[J].2005,23(28).
- [6]Pinder SE,Wencyk P,Sibbering DM,etc.Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival[J].1995.
- [7]R J, Zarbo,R E, Nakhleh,R D, Brown,etc.Prognostic significance of DNA ploidy and proliferation in 309 colorectal carcinomas as determined by two-color multiparametric DNA flow cytometry.[J].1997,79(11).
- [8]Houlston RS,Hubner R,Popat S.Systematic review of microsatellite instability and colorectal cancer prognosis.[J].2005,23(3).
- [9]Moch H,Nocito A,Bubendorf L,etc.Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies.[J].2001,195(1).
- [10]K, Handa,M, Yamakawa,H, Takeda,etc.Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prognosis.[J].1999,84.
- [11]M. Ilyas,J. Straub,I.P.M. Tomlinson,etc.Genetic pathways in colorectal and other cancers[J].1999,35(3).
- [12]Karamouzis MV,Grandis JR,Argiris A.Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.[J].2007,298(1).
- [13]Berger DH.Plasmin/plasminogen system in colorectal cancer.[J].2002,26(7).
- [14]L M, Ellis,Y, Takahashi,W, Liu,etc.Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications.[J].2000,5 Suppl 1.
- [15]Popat S,Chen Z,Chandler I,etc.A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer.[J].2006,17(12).
- [16]D C, Bicknell,L, Kaklamanis,R, Hampson,etc.Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas.[J].1996,6.
- [17]Mass RD,Kabbinavar FF,Sarkar S,etc.Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.[J].2005,23(16).
- [18]Scarpi E,Zoli W,Amadori D,etc.Role of biological markers in the clinical outcome of colon cancer.[J].2002,87(8).
- [19]Scott IS,Davies RJ,Miller R,etc.A novel immunohistochemical method to estimate cell-cycle phase distribution in archival tissue: implications for the prediction of outcome in colorectal cancer.[J].2003,201(2).
- [20]Heimdal K,Stormorken AT,Aase S,etc.Immunohistochemistry identifies carriers of mismatch repair gene defects causing hereditary nonpolyposis colorectal cancer.[J].2005,23(21).
- [21]Cascinu S,Graziano F.Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?[J].2003,14(7).